Published in Blood on September 08, 2005
Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood (2011) 3.30
Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A (2013) 3.25
Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004. Br J Haematol (2008) 3.21
Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol (2009) 2.95
Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood (2008) 2.49
Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature (2012) 2.36
Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood (2007) 2.31
B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood (2008) 2.18
Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood (2009) 2.16
Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer (2009) 2.01
Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol (2013) 1.70
Primary anaplastic large-cell lymphoma associated with breast implants. Leuk Lymphoma (2011) 1.68
Activating STAT6 mutations in follicular lymphoma. Blood (2014) 1.63
Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood (2007) 1.63
Diagnosis and treatment of primary CNS lymphoma. Nat Rev Neurol (2013) 1.56
Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol (2012) 1.53
Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer (2011) 1.53
18-Fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of 'indeterminate' reports. Leuk Lymphoma (2010) 1.47
Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project. Haematologica (2011) 1.43
Hodgkin lymphoma incidence in ethnic enclaves in California. Leuk Lymphoma (2015) 1.40
Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution. Diagn Pathol (2011) 1.38
Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr (2014) 1.30
Gene-nutrient interactions among determinants of folate and one-carbon metabolism on the risk of non-Hodgkin lymphoma: NCI-SEER case-control study. Blood (2007) 1.30
Prognostic factors in chronic lymphocytic leukemia-what do we need to know? Nat Rev Clin Oncol (2010) 1.30
The epidemic of non-Hodgkin lymphoma in the United States: disentangling the effect of HIV, 1992-2009. Cancer Epidemiol Biomarkers Prev (2013) 1.27
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol (2014) 1.26
Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer (2009) 1.24
Personal use of hair dye and the risk of certain subtypes of non-Hodgkin lymphoma. Am J Epidemiol (2008) 1.23
A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma. Blood (2009) 1.20
MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin Cancer Res (2011) 1.17
Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma. J Clin Oncol (2012) 1.17
Risk of lymphoma subtypes after solid organ transplantation in the United States. Br J Cancer (2013) 1.17
Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. Blood (2014) 1.16
Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network. J Clin Oncol (2008) 1.15
Occupational exposure to solvents and risk of non-Hodgkin lymphoma in Connecticut women. Am J Epidemiol (2008) 1.14
Chronic immune stimulation and subsequent Waldenström macroglobulinemia. Arch Intern Med (2008) 1.14
IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma. Blood (2008) 1.12
Refining tumor-associated aneuploidy through 'genomic recoding' of recurrent DNA copy number aberrations in 150 canine non-Hodgkin lymphomas. Leuk Lymphoma (2011) 1.09
Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma. Cancer Res (2012) 1.08
Incidence patterns and outcomes for hodgkin lymphoma patients in the United States. Adv Hematol (2010) 1.08
Autoimmune complications in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol (2010) 1.07
Racial/ethnic variation in EBV-positive classical Hodgkin lymphoma in California populations. Int J Cancer (2008) 1.07
Assessment of pre-diagnosis biomarkers of immune activation and inflammation: insights on the etiology of lymphoma. J Proteome Res (2010) 1.07
Polymorphisms in DNA repair and one-carbon metabolism genes and overall survival in diffuse large B-cell lymphoma and follicular lymphoma. Leukemia (2008) 1.07
Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network. Br J Cancer (2015) 1.04
Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study. Cytokine (2012) 1.03
Age at cancer diagnosis for blacks compared with whites in the United States. J Natl Cancer Inst (2015) 1.03
Lymphoid malignancies in U.S. Asians: incidence rate differences by birthplace and acculturation. Cancer Epidemiol Biomarkers Prev (2011) 1.03
Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk Res (2008) 1.03
Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival. Am J Hematol (2010) 1.01
Medical history, lifestyle, family history, and occupational risk factors for follicular lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr (2014) 1.01
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma. Oncotarget (2015) 1.00
Small intestinal cancer: a population-based study of incidence and survival patterns in the United States, 1992 to 2006. Cancer Epidemiol Biomarkers Prev (2010) 1.00
Racial/ethnic differences in cancer risk after kidney transplantation. Am J Transplant (2013) 0.98
Epigenomic evolution in diffuse large B-cell lymphomas. Nat Commun (2015) 0.98
Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr (2014) 0.97
Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas. Br J Haematol (2010) 0.97
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Mol Ther (2017) 0.96
The epidemiological features of lymphoid malignancies in Benin City, Nigeria: a 15 years study. Pan Afr Med J (2012) 0.96
Incidence of lymphoid neoplasms by subtype among six Asian ethnic groups in the United States, 1996-2004. Cancer Causes Control (2008) 0.96
Examining racial differences in diffuse large B-cell lymphoma presentation and survival. Leuk Lymphoma (2013) 0.95
PAK1 mediates resistance to PI3K inhibition in lymphomas. Clin Cancer Res (2013) 0.95
Development of query strategies to identify a histologic lymphoma subtype in a large linked database system. Cancer Inform (2007) 0.94
Pediatric Burkitt lymphoma presenting as acute pancreatitis: MRI characteristics. Pediatr Radiol (2010) 0.94
Risk Factors of Non-Hodgkin Lymphoma. Expert Opin Med Diagn (2011) 0.94
Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. Haematologica (2013) 0.94
Human immunodeficiency virus - associated lymphomas: a neglected domain. N Am J Med Sci (2013) 0.92
Blood transfusion, anesthesia, surgery and risk of non-Hodgkin lymphoma in a population-based case-control study. Int J Cancer (2008) 0.90
Treatment of diffuse large B-cell lymphoma in the elderly: regimens without anthracyclines are common and not futile. Leuk Lymphoma (2014) 0.90
Variable frequency of polyomavirus SV40 and herpesvirus EBV in lymphomas from two different urban population groups in Houston, TX. J Clin Virol (2009) 0.90
Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside. Oncologist (2012) 0.90
Hairy cell leukaemia: a heterogeneous disease? Br J Haematol (2008) 0.89
Mutated in colorectal cancer (MCC) is a novel oncogene in B lymphocytes. J Hematol Oncol (2014) 0.88
The utility of t(14;18) in understanding risk factors for non-Hodgkin lymphoma. J Natl Cancer Inst Monogr (2008) 0.88
Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma. Cancer Res (2013) 0.88
Hodgkin lymphoma among US solid organ transplant recipients. Transplantation (2010) 0.88
Reproductive factors and non-Hodgkin lymphoma risk in the California Teachers Study. PLoS One (2009) 0.87
Incidence of marginal zone lymphoma in the United States, 2001-2009 with a focus on primary anatomic site. Br J Haematol (2014) 0.87
Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. Leuk Lymphoma (2013) 0.87
Development of the Lymphoma Enterprise Architecture Database: a caBIG Silver level compliant system. Cancer Inform (2009) 0.87
Racial differences in three major NHL subtypes: descriptive epidemiology. Cancer Epidemiol (2015) 0.87
Pancytopenia in a 70-year-old african-american male: an unusual presentation of a rare disease. Case Rep Hematol (2014) 0.87
Risk factors for non-Hodgkin lymphoma subtypes defined by histology and t(14;18) in a population-based case-control study. Int J Cancer (2010) 0.87
A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. Ther Clin Risk Manag (2015) 0.87
Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches. Cancer Control (2012) 0.86
Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma. J Cancer Res Clin Oncol (2010) 0.86
Contributions of Subtypes of Non-Hodgkin Lymphoma to Mortality Trends. Cancer Epidemiol Biomarkers Prev (2015) 0.86
Hematopoietic stem cell transplantation for hematologic malignancies in older adults: geriatric principles in the transplant clinic. J Natl Compr Canc Netw (2014) 0.86
Genetic variation in N-acetyltransferases 1 and 2, cigarette smoking, and risk of non-Hodgkin lymphoma. Cancer Causes Control (2009) 0.85
No survival improvement for patients with angioimmunoblastic T-cell lymphoma over the past two decades: a population-based study of 1207 cases. PLoS One (2014) 0.85
Oral contraceptives, menopausal hormone therapy use and risk of B-cell non-Hodgkin lymphoma in the California Teachers Study. Int J Cancer (2010) 0.85
The physician-patient relationship and quality of life: lessons from chronic lymphocytic leukemia. Leuk Res (2008) 0.85
Impact of age and socioeconomic status on treatment and survival from aggressive lymphoma: a UK population-based study of diffuse large B-cell lymphoma. Cancer Epidemiol (2015) 0.85
PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol (2016) 0.85
Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. Haematologica (2013) 0.84
Age-period-cohort modelling of non-Hodgkin's lymphoma incidence in a French region: a period effect compatible with an environmental exposure. Environ Health (2010) 0.84
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
Inflammation and cancer. Nature (2002) 53.78
Cancer statistics, 2005. CA Cancer J Clin (2005) 25.65
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med (2002) 24.07
A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood (1994) 21.00
Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol (1976) 13.98
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood (2003) 13.92
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med (2004) 12.20
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood (2004) 11.07
A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood (1997) 11.04
Chronic lymphocytic leukemia. N Engl J Med (2005) 9.99
Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med (2004) 6.91
Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol (1997) 5.94
The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev (1999) 5.49
Spectrum of AIDS-associated malignant disorders. Lancet (1998) 5.30
Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst (2001) 4.26
Comparative analysis of two rates. Stat Med (1985) 4.25
Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst (2000) 3.47
Updated Kiel classification for lymphomas. Lancet (1988) 3.25
Graphical presentation of trends in rates. Am J Epidemiol (1995) 3.09
Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol (2004) 2.72
The epidemiology of non-Hodgkin's lymphoma. Oncogene (2004) 2.71
Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States. J Natl Cancer Inst (1999) 2.38
Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst (2002) 2.38
Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood (2001) 2.37
Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst (2000) 2.35
Mantle cell lymphoma-- an entity comes of age. Blood (1996) 2.30
BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol (2004) 2.20
Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group. J Clin Pathol (1989) 2.13
Focus on multiple myeloma. Cancer Cell (2004) 2.10
Racial and ethnic differences in the seroprevalence of 6 infectious diseases in the United States: data from NHANES III, 1988-1994. Am J Public Health (2004) 1.91
Projections of the incidence of non-Hodgkin's lymphoma related to acquired immunodeficiency syndrome. J Natl Cancer Inst (1991) 1.91
Cigarette smoking and risk of non-Hodgkin lymphoma: a pooled analysis from the International Lymphoma Epidemiology Consortium (interlymph). Cancer Epidemiol Biomarkers Prev (2005) 1.87
Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer (1997) 1.82
Changing incidence of non-Hodgkin lymphomas in the United States. Cancer (2002) 1.80
Epidemiology and genetics of childhood cancer. Oncogene (2004) 1.79
Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Res (1992) 1.78
Non-Hodgkin lymphoma: an update. Lancet Oncol (2004) 1.78
Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. AIDS (2001) 1.72
KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol (2004) 1.69
Human T-cell leukemia virus type I and adult T-cell leukemia. Oncogene (2003) 1.66
Helicobacter pylori and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood. Am J Gastroenterol (1997) 1.62
Is endemic Burkitt's lymphoma an alliance between three infections and a tumour promoter? Lancet Oncol (2004) 1.61
The epidemiology of non-Hodgkin's lymphoma: comparison of nodal and extra-nodal sites. Int J Cancer (1997) 1.57
Expert review of non-Hodgkin's lymphomas in a population-based cancer registry: reliability of diagnosis and subtype classifications. Cancer Epidemiol Biomarkers Prev (2004) 1.55
Hodgkin's and non-Hodgkin's lymphomas. Cancer Surv (1994) 1.55
Quantification of the impact of known risk factors on time trends in non-Hodgkin's lymphoma incidence. Cancer Res (1992) 1.54
Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. Cancer Epidemiol Biomarkers Prev (2006) 1.51
Inflamm-aging: autoimmunity, and the immune-risk phenotype. Autoimmun Rev (2004) 1.50
Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data. Cancer (2001) 1.48
The gastric marginal zone B-cell lymphoma of MALT type. Blood (2000) 1.47
Epidemiology of non-Hodgkin lymphoma in Connecticut. 1935-1988. Cancer (1992) 1.44
Immune-related conditions and immune-modulating medications as risk factors for non-Hodgkin's lymphoma: a case-control study. Am J Epidemiol (2005) 1.36
The rise in incidence of lymphomas in Europe 1985-1992. Eur J Cancer (1999) 1.34
Gene expression profiling of diffuse large B-cell lymphoma. Leuk Lymphoma (2003) 1.33
Epidemiology of Hodgkin's disease: a review. Hematol Oncol (2004) 1.23
Gender and age-related differences in Burkitt lymphoma--epidemiological and clinical data from The Netherlands. Eur J Cancer (2004) 1.23
Increasing incidence and descriptive epidemiology of extranodal non-Hodgkin lymphoma in parts of England and Wales. Hematol J (2002) 1.19
Epidemiology of the Revised European-American Lymphoma Classification subtypes. Epidemiol Rev (1998) 1.18
Cancer in children of nuclear industry employees: report on children aged under 25 years from nuclear industry family study. BMJ (1999) 1.15
Increasing incidence of non-Hodgkin's lymphoma in Canada, 1970-1996: age-period-cohort analysis. Hematol Oncol (2003) 1.13
The incidence of non-Hodgkin's lymphoma and its histologic subtypes in Asian migrants to the United States and their descendants. Cancer Causes Control (1996) 1.09
Time trends in Hodgkin's disease incidence. The role of diagnostic accuracy. Cancer (1990) 1.09
Non-Hodgkin's lymphoma. Cancer (1995) 1.08
Incidence of non-Hodgkin's lymphoma and Hodgkin's disease in Sardinia, Italy: 1974-1993. Haematologica (2001) 1.04
Is the decline of the increasing incidence of non-Hodgkin lymphoma in Sweden and other countries a result of cancer preventive measures? Environ Health Perspect (2003) 1.02
Mantle cell lymphoma. Curr Opin Hematol (2004) 1.02
The increase of Hodgkin's disease incidence among young adults. Experience in Connecticut, 1935-1992. Cancer (1997) 1.00
Incidence of leukemia in Asian migrants to the United States and their descendants. Cancer Causes Control (2002) 1.00
AIDS-related cancers in the era of highly active antiretroviral therapy. Oncology (Williston Park) (2001) 0.99
Historical review of lymphomas. Br J Haematol (2000) 0.99
Incidence and spectrum of non-Hodgkin lymphoma in Chinese migrants to British Columbia. Br J Haematol (2005) 0.95
Who is WHO and what was REAL? Swiss Med Wkly (2002) 0.91
Chronic leukaemias. Baillieres Clin Haematol (1992) 0.90
Time trends in incidence of haematological malignancies and related conditions. Br J Haematol (1999) 0.89
Non-Hodgkin's lymphoma: an analysis of the Metropolitan Detroit SEER database. Cancer Invest (2000) 0.89
Cancer occurrence in Southeast Asian children in California. J Pediatr Hematol Oncol (2004) 0.88
AIDS-related cancer in the era of highly active antiretroviral therapy (HAART): a model of the interplay of the immune system, virus, and cancer. "On the offensive--the Trojan Horse is being destroyed"--Part B: Malignant lymphoma. Cancer Invest (2004) 0.83
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med (2002) 24.07
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood (2003) 13.92
Body-mass index and mortality among 1.46 million white adults. N Engl J Med (2010) 13.34
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med (2004) 12.20
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature (2010) 8.78
Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med (2010) 8.74
Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev (2009) 8.08
50-year trends in smoking-related mortality in the United States. N Engl J Med (2013) 7.80
Reporting participation in epidemiologic studies: a survey of practice. Am J Epidemiol (2005) 6.52
Epidemiologic evaluation of measurement data in the presence of detection limits. Environ Health Perspect (2004) 6.43
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell (2003) 6.11
Molecular diagnosis of Burkitt's lymphoma. N Engl J Med (2006) 6.10
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med (2003) 6.06
Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst (2008) 6.00
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A (2008) 5.90
Performance of common genetic variants in breast-cancer risk models. N Engl J Med (2010) 5.79
Smoking and mortality--beyond established causes. N Engl J Med (2015) 5.54
Epidemiology and risk factors for kidney cancer. Nat Rev Urol (2010) 5.25
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst (2009) 4.72
Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet (2016) 4.49
Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA (2002) 4.39
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature (2012) 4.33
Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst (2005) 4.14
Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol (2006) 4.13
A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res (2009) 3.87
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst (2005) 3.75
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am (2002) 3.69
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol (2012) 3.59
Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood (2008) 3.56
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) (2011) 3.33
Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood (2011) 3.30
Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood (2005) 3.25
Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol (2005) 3.25
A road map for efficient and reliable human genome epidemiology. Nat Genet (2006) 3.21
Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004. Br J Haematol (2008) 3.21
Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer (2009) 3.15
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood (2005) 3.12
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) (2011) 3.03
Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol (2005) 3.01
Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics. Cancer (2012) 2.95
Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol (2010) 2.86
Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: An analysis of 26,758 cases. Int J Cancer (2006) 2.73
Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst (2004) 2.60
Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome. Breast Cancer Res Treat (2005) 2.57
Transforming epidemiology for 21st century medicine and public health. Cancer Epidemiol Biomarkers Prev (2013) 2.56
Sex disparities in cancer incidence by period and age. Cancer Epidemiol Biomarkers Prev (2009) 2.50
Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood (2008) 2.49
Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. Thyroid (2010) 2.48
Positional accuracy of two methods of geocoding. Epidemiology (2005) 2.47
US lung cancer trends by histologic type. Cancer (2014) 2.46
Trends in the incidence of testicular germ cell tumors in the United States. Cancer (2003) 2.45
Leisure time physical activity of moderate to vigorous intensity and mortality: a large pooled cohort analysis. PLoS Med (2012) 2.45
Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell (2010) 2.43
Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood (2009) 2.43
Dietary patterns and adenocarcinoma of the esophagus and distal stomach. Am J Clin Nutr (2002) 2.40
Contemporary epidemiology of renal cell cancer. Cancer J (2008) 2.40
Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst (2002) 2.38
Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet (2010) 2.37
Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980-2007. JAMA (2011) 2.31
Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol (2010) 2.30
Alcohol consumption and risk of non-Hodgkin lymphoma: a pooled analysis. Lancet Oncol (2005) 2.27
Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood (2011) 2.25
Early life exposure to diagnostic radiation and ultrasound scans and risk of childhood cancer: case-control study. BMJ (2011) 2.21
InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood (2010) 2.21
BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol (2004) 2.20
Trends in U.S. pleural mesothelioma incidence rates following simian virus 40 contamination of early poliovirus vaccines. J Natl Cancer Inst (2003) 2.19
Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood (2005) 2.19
Risk of non-Hodgkin's lymphoma and family history of lymphatic, hematologic, and other cancers. Cancer Epidemiol Biomarkers Prev (2004) 2.19
Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood (2009) 2.16
Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer (2007) 2.16
Adverse health outcomes in women exposed in utero to diethylstilbestrol. N Engl J Med (2011) 2.16
Consumption of aspartame-containing beverages and incidence of hematopoietic and brain malignancies. Cancer Epidemiol Biomarkers Prev (2006) 2.15
Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol (2008) 2.15
Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood (2010) 2.12
AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology? Blood (2010) 2.10
Projecting the performance of risk prediction based on polygenic analyses of genome-wide association studies. Nat Genet (2013) 2.09
Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol (2008) 2.08
Cancer incidence in the US radiologic technologists health study, 1983-1998. Cancer (2003) 2.08
International trends in the incidence of testicular cancer, 1973-2002. Cancer Epidemiol Biomarkers Prev (2010) 2.07
Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res (2006) 2.06